Introduction
============

The prostamide bimatoprost 0.03% and the prostaglandin analogs travoprost 0.004% and latanoprost 0.005% are ocular hypotensive lipids, the newest class of drugs indicated for the lowering of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension. These medications, administered once daily, have greater IOP-lowering efficacy than the beta-blocker timolol.[@b1-opth-4-1131]--[@b3-opth-4-1131]

Due to the importance of even small increments of IOP reduction for preservation of visual function among those with glaucoma or ocular hypertension, patients who are not achieving sufficiently low IOP with their current medications may benefit from trying a new regimen. To avoid delay in determining the effect of such changes, a paired-eye comparison was used to assess the efficacy of prostaglandin/prostamide medications in patients who had uncontrolled or poorly controlled IOP.

Methods
=======

This retrospective chart review of patients participating in individual, within-practice, paired-eye, open-label comparisons included consecutive patients seen at a private practice clinic between September 2002 and May 2005. Patients had a diagnosis of glaucoma or ocular hypertension and their IOP had been uncontrolled in the investigator's clinical judgment. Patients had been clinically judged to be suitable candidates for therapy with agents of the prostamide/prostaglandin class. The three medications studied in this evaluation were bimatoprost 0.03% (Lumigan^®^; Allergan, Inc., Irvine, CA), travoprost 0.004% (Travatan^®^; Alcon Laboratories, Inc., Fort Worth, TX), and latanoprost 0.005% (Xalatan^®^, Pfizer, Inc., New York, NY). Patients were assigned to bimatoprost in one randomly assigned eye and another medication in the fellow eye. The second medication was determined at random, except for patients who were already using one of the prostaglandin/prostamide analogs. These patients switched to use the other two medications.

Patients included in this evaluation were examined by the physician and had IOP measured at the initial visit. Per clinical routine, patients were scheduled for a follow-up visit 4--6 weeks later, when IOP was measured and hyperemia or other side effects were recorded. At the follow-up visit, patients were asked about the eye drops in a general way such as, "How are you doing with the new drops?" or "How are your new drops?" the physician then discussed with each patient the IOP findings for each eye and other aspects of the treatment. After conferring with the physician, patients determined which medication they elected to continue with for their ongoing glaucoma therapy. In some cases, a reason for the patient's choice was noted in the chart. Patient charts were excluded from analysis if they had any ocular surgery between the initial and follow-up visit. The main outcome measures of the chart review were mean change in IOP from baseline, and percentage of patients choosing a particular medication for continued use. Descriptive statistics were calculated. Unpaired *t*-tests were used to evaluate the statistical significance of IOP changes from baseline within a treatment group, and paired *t*-tests were performed to determine statistical significance among treatment groups in the bilateral comparison. *P* values less than 0.05 were considered statistically significant.

Results
=======

Study population
----------------

A total of 91 patients participated in the paired-eye comparison. Of these, 36 were excluded from the chart review analysis; 17 patients' charts were not available at the time of data collection, seven did not have follow-up data, four did not have a confirmatory diagnosis, three did not receive bimatoprost in one of the eyes, two had eye surgery between the baseline and follow-up visit, two patients did not make a clear choice and proceeded to use both study agents, and one individual only used one of the comparative agents.

Fifty patients received bimatoprost in one eye and travoprost in the other eye, and five patients received bimatoprost in one eye and latanoprost in the other eye. Bimatoprost was randomized to the right eye in 30 patients and to the left eye in 25 patients; travoprost was randomized to the right eye in 22 patients and to the left eye in 28 patients; and latanoprost was randomized to the right eye in three patients and to the left eye in two patients. Patient demographics are summarized in [Table 1](#t1-opth-4-1131){ref-type="table"}.

Seventy-five percent of patients were taking at least one glaucoma medication, with 42% of patients on monotherapy and 35% (19/55) using two or more medications ([Table 2](#t2-opth-4-1131){ref-type="table"}). Because the majority of patients (58%, 32/55) were using latanoprost prior to enrolling in the study ([Table 2](#t2-opth-4-1131){ref-type="table"}), few participants were assigned to receive latanoprost during the study.

The median interval between the baseline and follow-up visits was 42 days (mean 72.7 days), and 10 patients had their follow-up visit more than 90 days after the baseline visit. Data were obtained for all outcome measures for all patients, except for three patients receiving bilateral bimatoprost or travoprost, for whom IOP-lowering data were not documented in the medical chart at the follow-up visit.

IOP reduction
-------------

Bimatoprost and travoprost significantly reduced IOP from baseline during the study period ([Figure 1](#f1-opth-4-1131){ref-type="fig"}). For eyes receiving bimatoprost with documented IOP measurement at baseline and at follow-up (n = 52), IOP decreased by 2.7 mmHg (standard deviation = 4.2 mmHg), a significant reduction (*P* \< 0.0001) versus baseline. Mean (±standard deviation) baseline IOP for bimatoprost-treated eyes was 19.8 ± 4.9 mmHg (range 10--34) and dropped to 17.1 ± 4.9 mmHg (range 19--37) at the end of the study period. For travoprost-treated eyes with documented IOP measurement at baseline and at follow-up (n = 47), IOP was reduced from a baseline value of 19.4 ± 4.1 mmHg (range 12--31) to 17.7 ± 4.2 mmHg (range 9--29) at the end of the study period, for a decrease of 1.7 mmHg (*P* = 0.009 versus baseline). The numeric magnitude of mean IOP reduction with bimatoprost was larger than with travoprost (2.7 mmHg versus 1.7 mmHg decrease), but the difference did not reach statistical significance (*P* = 0.230).

In eyes receiving latanoprost (n = 5), mean baseline IOP was 19.6 ± 4.7 mmHg (range 15--26), and IOP at follow-up averaged 16.2 ± 2.5 mmHg (range 14--20), for a reduction of 3.4 ± 3.2 mmHg. This difference was not statistically significant (*P* = 0.077), probably because of the small sample size.

Patient choices of medication
-----------------------------

At the follow-up visit, the physician discussed the clinical outcomes with each patient, and each patient chose which medication they would prefer to continue using. Patients who received bimatoprost in one eye and travoprost in the fellow eye chose to continue with bimatoprost over travoprost by a factor of 2.4 to 1 ([Figure 2](#f2-opth-4-1131){ref-type="fig"}). Nearly seven of 10 patients chose bimatoprost (68%, 34/50), 28% of patients (14/50) chose travoprost, and 4% (2/50) chose neither. The two patients who chose neither option had used latanoprost prior to the study, and elected to continue with it afterwards. Among the five patients who received bilateral bimatoprost or latanoprost, three chose to continue with bimatoprost, one chose latanoprost, and one chose neither (this patient had been using travoprost prior to the study and chose to continue with it).

[Table 3](#t3-opth-4-1131){ref-type="table"} shows the primary factor that patients stated influenced their choice of medication. Among the 15 patients who stated a reason, most (80%, 12/15) cited improvement in IOP as the primary factor in their decision. A majority of these patients (83%, 10/12) preferred bimatoprost over the agent they had used in the fellow eye.

Other reasons offered by patients for determination of medication choice were "pressure change plus better side effect profile", "convenience", and "price", cited by one patient each (medications chosen were travoprost, and latanoprost, respectively). No patients cited "side effect profile" as a primary influence on their medication choice. Looking at the entire study population analyzed (n = 55), hyperemia was reported by eight patients, with six reporting hyperemia in both eyes, one reporting hyperemia in the bimatoprost-treated eye only, and one reporting hyperemia in the travoprost-treated eye only.

Discussion
==========

Patients with glaucoma or ocular hypertension who did not have sufficient IOP control with their current medication regimens instilled bimatoprost in one eye and either travoprost or latanoprost in the other eye. Significant IOP reductions were observed for bimatoprost- and travoprost-treated eyes, consistent with published results.[@b1-opth-4-1131]--[@b4-opth-4-1131]

Relatively few studies have directly compared the efficacy of prostaglandin/prostamide glaucoma therapies. In a meta-analysis of all head-to-head randomized, investigator-masked direct comparisons of latanoprost, bimatoprost, and travoprost, bimatoprost was more efficacious at lowering IOP than travoprost in the two direct comparisons identified (involving 150 patients), and bimatoprost was found to be more efficacious than latanoprost in six head-to-head studies identified (involving 460 patients).[@b4-opth-4-1131] Our study may not have been adequately powered to detect statistically significant differences among therapies. However, for the two therapies where we detected a significant IOP decline from baseline (bimatoprost and travoprost), bimatoprost showed qualitatively greater IOP reduction than travoprost, consistent with a report by Holmstrom et al.[@b4-opth-4-1131]

An important limitation of this assessment was the fact that relatively few eyes were randomized to receive latanoprost. Because nearly 60% of study participants had been receiving latanoprost prior to the study, only five patients received latanoprost as one of the comparators. Therefore, for these patients, the bilateral comparison was limited to travoprost and bimatoprost. Because of the small sample size, the results with latanoprost may be difficult to generalize. Use of a larger study population, or employment of a multiple-study site design in future trials may result in a patient population that is more evenly distributed among the cohorts.

It should be noted that our results are consistent with those of a large-scale "real-world" study, in which more than 15,000 glaucoma patients on latanoprost were switched to bimatoprost in a nationwide health maintenance organization.[@b5-opth-4-1131] In that study, patients switching to bimatoprost experienced statistically significant IOP reduction, and few reverted to their previous medication.[@b5-opth-4-1131]

Nonadherence to glaucoma treatment regimens is a significant problem, in large part because glaucoma is chronic, progressive, and symptom-free in its early stages.[@b6-opth-4-1131]--[@b8-opth-4-1131] In the treatment practice described in this report, patients chose which medication to continue using after consulting with the physician. The patient--physician partnership in medical decision-making is increasing as patients become more empowered through consumerism and access to independent information resources, such as the Internet.[@b9-opth-4-1131] A majority of patients in this study who gave a reason for their choice cited IOP-lowering efficacy, as opposed to side effects or other aspects of the medication immediately perceptible to the patient. Our results, while preliminary, raise the intriguing question of whether patients who are involved in their medical decision-making might also have improved adherence to their glaucoma regimens. Further study may be warranted.

Conclusion
==========

After direct comparisons between glaucoma drugs trialed in each eye, patients preferred bimatoprost over travoprost by a factor of 2.4 to 1. Today's therapeutic armamentarium offers multiple choices for achieving target IOP. Physicians may wish to consider a simple bilateral trial such as ours for their glaucoma patients who are not achieving adequate IOP control with their current medication regimens.
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![Change in mean IOP from baseline. IOP reduction seen over 4--6 weeks of QD treatment. Baseline mean IOP: bimatoprost 19.8 mmHg; travoprost 19.4 mmHg. Follow-up IOP: bimatoprost 17.1 mmHg; travoprost 17.2 mmHg. *p* = 0.230 for bimatoprost versus travoprost change bilateral paired-eye analysis of change in IOP from baseline.\
**Abbreviation:** IOP, intraocular pressure.](opth-4-1131f1){#f1-opth-4-1131}

![Glaucoma medications chosen by patients. After 4--6 weeks of bilateral glaucoma therapy, patients chose which medication they would prefer to continue using as their ongoing regimen. Data shown are for patients who received bimatoprost in one eye and travoprost in the fellow eye.](opth-4-1131f2){#f2-opth-4-1131}

###### 

Patient demographics

  -------------------------------------------------------------- ------ ----------
  Patients (n)                                                   55     
  Mean age, years (range)                                        67     (27--90)
  Mean years with glaucoma                                       9.35   
  Gender, n (%)                                                         
   Female                                                        31     56.4%
   Male                                                          24     43.6%
  Race, n (%)                                                           
   White/Caucasian                                               20     36.4%
   Hispanic                                                      11     20.0%
   Asian/Pacific Islander                                        10     18.2%
   Black/African American                                        7      12.7%
   Not recorded                                                  7      12.7%
  Diagnosis, n (%)[\*](#tfn1-opth-4-1131){ref-type="table-fn"}          
   Chronic open-angle glaucoma                                   30     54.5%
   Ocular hypertension                                           14     25.5%
   Low- or normal-tension glaucoma                               7      10.5%
   Narrow-angle glaucoma                                         4      7.3%
   Pigmentary                                                    4      7.3%
   Chronic angle-closure glaucoma                                2      3.6%
   Suspected glaucoma                                            1      1.8%
   Neovascular glaucoma                                          1      1.8%
  -------------------------------------------------------------- ------ ----------

**Note:** Some patients had a diagnosis of more than one type of glaucoma.

###### 

Glaucoma medications used prior to study

                                                                     n    \%
  ------------------------------------------------------------------ ---- -------
  Number of medications                                                   
   0                                                                 13   23.7%
   1                                                                 23   41.8%
   2                                                                 11   20.0%
   3                                                                 7    12.7%
   4                                                                 1    1.8%
  Previous medications[\*](#tfn2-opth-4-1131){ref-type="table-fn"}        
   Latanoprost                                                       32   58.2%
   Brimonidine/adrenergic agonist                                    11   20.0%
   Dorzolamide/timolol combination                                   10   18.2%
   Timolol/beta-blocker                                              10   18.2%
   Dorzolamide/carbonic anhydrase inhibitor                          5    9.1%
   Carbachol                                                         1    1.8%
   Travoprost                                                        1    1.8%

**Note:** Some patients were receiving more than one medication prior to study therapy.

###### 

Factors in patients' choice of glaucoma medication

  ------------------------------------------------- ---- -------
  Reasons not stated                                40   72.7%
  Reasons stated                                    15   27.3%
  Specific reasons (n = 15)                              
   IOP improvement                                  12   80.0%
   Side effect profile                              0    0.0%
   IOP improvement and better side effect profile   1    6.7%
   Convenience                                      1    6.7%
   Price                                            1    6.7%
  ------------------------------------------------- ---- -------

**Abbreviation:** IOP, intraocular pressure.
